Navigation Links
Solta Medical Reports Second Quarter Results
Date:8/2/2011

HAYWARD, Calif., Aug. 2, 2011 /PRNewswire/ -- Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the second quarter ended June 30, 2011. Second quarter 2011 revenue was $29.0 million, compared to $30.1 million in the same period last year. Revenue from the sales of treatment tips and consumables grew 10% as compared to the second quarter of 2010, and accounted for 55% of total revenue.  

GAAP net loss for the quarter was $0.2 million, or approximately breakeven per share, as compared to GAAP net income of $1.5 million, or $0.02 per diluted share, for the second quarter of 2010. Non-GAAP net income for the quarter was $1.4 million, or $0.02 per diluted share, as compared to non-GAAP net income of $3.8 million, or $0.06 per diluted share, for the same period last year. The previous year’s GAAP and non-GAAP operating results included a gain on litigation settlement of $2.2 million.

Solta Medical’s GAAP results for the second quarter include non-cash amortization and other acquisition related charges of $0.8 million and, non-cash stock based compensation charges of $0.8 million. The Company provides non-GAAP financial measures that exclude these charges and expenses. A reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

“Sales of our treatment tips and consumables were up year-over-year in every region around the world and resulted in an improvement to our gross margin as compared to last year’s second quarter. We also produced our seventh consecutive quarter of non-GAAP operating income,” said Stephen J. Fanning, Chairman, President, & CEO. “New system sales of our flagship Fraxel re:store Dual® and Thermage CPT® systems grew by double-digits in the quarter. In addition, we achieved double-digit product revenue growth from our direct markets in Europe and Latin America business units. However, sales of system upgrades were down year-over-year and we continued to experience below plan performance in Japan which we believe is attributable to the unfortunate events in March. With regard to system upgrades, we have implemented an aggressive sales incentive program to convert our remaining customer base with legacy systems to the latest Fraxel and Thermage technologies.”

“We are executing several strategies to advance top-line growth in the second half of the year,” continued Mr. Fanning. “We recently initiated commercial shipments of our innovative, new Clear + Brilliant skin rejuvenation platform which is gaining momentum with physicians and aesthetic practitioners worldwide. In June, we also ramped production and expanded the distribution of our personal care acne device, CLARO®, to additional Nordstrom stores and Sephora on-line. We expect CLARO to be available at Sephora retail stores beginning this quarter. Finally, we expect Philips to introduce our jointly developed, breakthrough laser skin rejuvenation device for the home, ReAura®, to the European market in September.”

Financial Outlook for 2011An update to the Company’s financial outlook for 2011 is as follows:

  • Revenue for the full year 2011 in the range of $115 million to $120 million, representing an increase of 4% to 8% from 2010 revenue. The company expects year-over-year revenue growth in the range of 8% to 17% for the last half of 2011. The revenue growth in the second half of the year is projected to be driven by recently introduced new products. The company’s previous revenue outlook for the full year 2011 was a range of $118 million to $123 million.
  • The outlook for non-GAAP gross margin in the range of 66% to 68% for the full year 2011 remains unchanged from the Company’s previously issued outlook. Non-GAAP gross margin excludes non-cash amortization charges, non-cash stock based compensation charges, and acquisition related adjustments. Non-GAAP gross margin for the six months ended June 30, 2011 was approximately 69%.
  • The outlook for positive non-GAAP EBITDA for every quarter and for the full-year 2011 remains unchanged from the Company’s previously issued outlook. Non-GAAP EBITDA excludes non-cash amortization charges, non-cash stock based compensation charges, and acquisition related adjustments. The company generated non-GAAP EBITDA for the first and second quarters of 2011 of $1.5 million and $2.2 million, respectively.

  • Non-GAAP PresentationTo supplement the condensed consolidated financial information presented on a GAAP basis, management has provided non-GAAP gross margin, non-GAAP operating income (loss), non-GAAP EBITDA, non-GAAP net income (loss) and non-GAAP earnings (loss) per share measures that exclude the impact of acquisition related adjustments, severance costs, acquisition related costs, and stock-based compensation expenses.  The Company believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of the Company’s ongoing operating results and trends, compared with historical results.  This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets.  There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures attached to this release.

    Conference Call Information The Company will also host a conference call and webcast today, Tuesday, August 2, 2011, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results and current corporate developments.  The dial-in number for the conference call is 877-941-0844 for domestic participants and 480-629-9835 for international participants.

    To access the live webcast of the call, go to Solta Medical’s website at www.solta.com and click on Investor Relations.  An archived webcast will also be available at www.solta.com.  

    About Solta Medical, Inc.Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's four premier brands: Thermage®, Fraxel®, Isolaz®, and CLARO®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the first laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the first FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. Since 2002, over one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.

    Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our financial outlook for 2011, our intent to convert customers with legacy systems to the latest Fraxel and Thermage technologies, and our expectations that Phillips will introduce a product jointly developed with us, and that our products will be available at Sephora retail stores. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Factors that might cause such a difference include the risk that physician adoption of our systems does not grow, the risk that customers do not continue to purchase treatment tips, the possibility that the market for the sale of new products does not develop as expected, and the risks relating to Solta Medical's ability to achieve its stated financial goals as a result of, among other things, economic conditions and consumer and physician confidence causing changes in consumer and physician spending habits that affect demand for our products and treatments. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2010, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.Solta Medical, Inc.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands of dollars, except share and per share data)(unaudited)Three Months EndedSix Months EndedJune 30,June 30,2011201020112010Net revenue

    $28,954$30,080$55,405$56,015Cost of revenue

    10,39111,35818,78120,500Gross margin

    18,56318,72236,62435,515Operating expenses:Sales and marketing

    11,91511,42923,73321,317Research and development

    3,6484,2767,2138,395General and administrative

    3,1243,2286,8507,712Legal settlement gain

    -(2,241)-(2,213)Total operating expenses

    18,68716,69237,79635,211Income (loss) from operations

    (124)2,030(1,172)304Interest income

    19113318Interest expense

    (21)(57)(74)(118)Other income and expense, net

    (9)(228)118(317)Income (loss) before income taxes

    (135)1,756(1,095)(113)Provision for income taxes

    71247136311Net income (loss)

    ($206)$1,509($1,231)($424)Net income (loss) per share - basic

    ($0.00)$0.03($0.02)($0.01)Net income (loss) per share - diluted

    ($0.00)$0.02($0.02)($0.01)Weighted average shares outstanding used in calculating net income(loss) per share:Basic

    60,634,84959,437,03860,269,80458,229,078Diluted

    60,634,84961,530,08560,269,80458,229,078Solta Medical, Inc.NON-GAAP RECONCILIATION OF GROSS MARGIN, OPERATING INCOME (LOSS), EBITDA, NET
    INCOME (LOSS) AND NET INCOME (LOSS) PER SHARE(in thousands, except share and per share data)(unaudited)Three Months EndedSix Months EndedJune 30,June 30,2011201020112010GAAP Gross margin

    $18,563$18,722$36,624$35,515GAAP gross margin as % of sales

    64%62%66%63%Non-GAAP adjustments to gross margin:GAAP Gross margin

    $18,563$18,722$36,624$35,515Amortization and other non-cash acquisition related charges

    8441,1421,6892,002Stock-based compensation

    9568164142Non-GAAP gross margin

    $19,502$19,932$38,477$37,659Non-GAAP gross margin as % of sales

    67%66%69%67%GAAP income (loss) from operations

    ($124)$2,030($1,172)$304Non-GAAP adjustments to net income (loss) from operations:Amortization and other non-cash acquisition related charges

    6441,4301,7182,651Severance expenses

    -55-55Acquisition-related expenses

    120139120963Stock-based compensation

    8126181,4811,320Non-GAAP income from operations

    $1,452$4,272$2,147$5,293Depreciation expenses

    7637421,5451,398Non-GAAP EBITDA

    $2,215$5,014$3,692$6,691GAAP net income (loss)

    ($206)$1,509($1,231)($424)Non-GAAP adjustments to net income (loss):Amortization and other non-cash acquisition related charges

    6441,4301,7182,651Severance expenses

    -55-55Acquisition-related expenses

    120139120963Stock-based compensation

    8126181,4811,320Non-GAAP net income

    $1,370$3,751$2,088$4,565GAAP basic net income (loss) per share

    ($0.00)$0.03($0.02)($0.01)Non-GAAP adjustments to basic income (loss) per share:Amortization and other non-cash acquisition related charges

    $0.01$0.02$0.03$0.05Severance expenses

    $0.00$0.00$0.00$0.00Acquisition-related expenses

    $0.00$0.00$0.00$0.02Stock-based compensation

    $0.01$0.01$0.02$0.02Non-GAAP basic net income per share

    $0.02$0.06$0.03$0.08Non-GAAP diluted net income per share

    $0.02$0.06$0.03$0.08GAAP weighted average shares outstanding used in calculating basic net income (loss) per share

    60,634,84959,437,03860,269,80458,229,078GAAP weighted average shares outstanding used in calculating diluted net income (loss) per share

    60,634,84961,530,08560,269,80458,229,078Adjustments for dilutive potential common stock

    4,795,261888,1094,497,5892,049,456Weighted average shares outstanding used in calculating non-GAAP diluted net income per share

    65,430,11062,418,19464,767,39360,278,534Solta Medical, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands of dollars, except share and per share data)(unaudited)June 30,December 31,20112010ASSETSCurrent assets:Cash and cash equivalents

    $37,108$36,898Accounts receivable

    13,21912,426Inventories

    13,54110,549Prepaid expenses and other current assets

    6,2415,906Total current assets

    70,10965,779Property and equipment, net

    5,3496,227Purchased intangible assets, net

    34,62436,809Goodwill

    49,48149,481Other assets

    578249Total assets

    $160,141$158,545LIABILITIES AND STOCKHOLDERS’ EQUITYLiabilities:Accounts payable

    $7,379$6,358Accrued liabilities

    10,66612,030Current portion of deferred revenue

    4,4403,428Short-term borrowings

    8,8749,528Customer deposits

    666441Total current liabilities

    32,02531,785Deferred revenue, net of current portion

    811969Term loan, net of current portion

    -98Non-current tax liabilities

    3,3993,372Other  liabilities

    137177Total liabilities

    36,37236,401Stockholders’ equity:Common stock, $0.001 par value:100,000,000 shares authorized 60,743,211 and 59,728,410 shares issued and outstanding at June 30, 2011 and December 31, 2010

    6160Additional paid-in capital

    196,053193,198Accumulated deficit

    (72,345)(71,114)Total stockholders’ equity

    123,769122,144Total liabilities and stockholders’ equity

    $160,141$158,545
    '/>"/>

    SOURCE Solta Medical, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Solta Medical Reports First Quarter Results
    2. Solta Medical to Present at the JMP Securities Research Conference
    3. Solta Medical Announces First Quarter 2011 Results Release and Conference Call
    4. Solta Medical Reports Fourth Quarter and Full Year 2010 Results
    5. Solta Medical Announces Full Year and Fourth Quarter 2010 Results Release and Conference Call
    6. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
    7. Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices
    8. Solta Medical Reports Third Quarter 2010 Results
    9. Solta Medical Announces FDA 510(k) Clearance of Fraxel re:store Dual Laser System for the Treatment of Actinic Keratosis
    10. Len DeBenedictis Retires as Chief Technology Officer of Solta Medical, Inc.
    11. Solta Medical, Inc. Announces Second Quarter 2010 Results Release Date and Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
    (Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
    (Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
    (Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
    (Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
    (Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
    Breaking Medicine News(10 mins):